Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1326 studies found for:    Multiple Sclerosis
Show Display Options
Rank Status Study
21 Enrolling by invitation Impact of Vitamin A on Multiple Sclerosis (MS)
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Dietary Supplement: vitamin A;   Drug: Drug: placebo
22 Completed
Has Results
Duloxetine for Multiple Sclerosis Pain
Condition: Multiple Sclerosis
Interventions: Drug: Duloxetine Hydrochloride (HCI);   Drug: Placebo
23 Completed Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy
Conditions: Multiple Sclerosis;   Peripheral Neuropathy
Intervention: Behavioral: Meditation instruction and practice
24 Active, not recruiting Improving Hand Use in Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Behavioral: CI Therapy;   Behavioral: CAM treatments
25 Completed
Has Results
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Drug: Fingolimod;   Drug: Standard MS DMTs
26 Completed
Has Results
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon beta-1a (Rebif)
27 Completed Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
Conditions: Multiple Sclerosis;   Optic Neuritis;   Transverse Myelitis;   Acute Brainstem/Cerebellar Syndrome
Intervention: Drug: interferon beta 1a 30 ug IM once weekly
28 Unknown  Combination Therapy of Betaseron-Prograf in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1b and Tacrolimus
29 Recruiting Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist
Condition: Multiple Sclerosis
Intervention:
30 Recruiting A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
Conditions: Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Clinically Isolated Syndrome
Intervention:
31 Completed Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon-1beta (Betaseron, BAY86-5046)
32 Completed An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers
Condition: Multiple Sclerosis
Intervention:
33 Completed
Has Results
A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: CNTO 1275
34 Not yet recruiting Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients
Condition: Multiple Sclerosis
Intervention: Biological: Blood samples
35 Completed Auditory Function in Patients With and Without Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Procedure: Hearing in Multiple Sclerosis
36 Not yet recruiting Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Dietary Supplement: Vitamin D3;   Dietary Supplement: Placebo
37 Active, not recruiting An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: alemtuzumab
38 Completed Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: alemtuzumab;   Biological: interferon beta-1a (Rebif®)
39 Completed Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: alemtuzumab;   Biological: interferon beta-1a (Rebif®)
40 Completed
Has Results
Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Dietary Supplement: Vitamin A;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years